ALEXANDRIA, Va., Feb. 3 -- United States Patent no. 12,539,299, issued on Feb. 3, was assigned to AstraZeneca AB (Sodertalje, Sweden).
"Oral formulation of a therapeutic compound" was invented by Cecilia Gunnarsson (Molndal, Sweden), Magnus Swenson (Sodertalje, Sweden), Hanna Matic (Sodertalje, Sweden), John Salomonsson (Sodertalje, Sweden) and Eva Karlsson (Sodertalje, Sweden).
According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides a pharmaceutical tablet formulation of tenapanor that is chemically stable and soluble comprising greater than about 6% w/w of amorphous tenapanor in its bis-HCl form, an acidifying agent, an antioxidant, a disintegrant, a lubricant, a glidant, a filler, and ...